CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Merrimack
Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will
present preclinical and clinical data from its oncology pipeline at
the 2017 American Association for Cancer Research (AACR) Annual
Meeting, April 1-5, 2017 at the
Walter E. Washington Convention Center,
Washington, D.C.. Of particular focus will be data on
MM-310, an antibody-directed nanotherapeutic (ADN) that entered
clinical development last week with the initiation of a Phase 1
study in solid tumors.
MM-310 delivers a novel taxane and targets EphA2, a tumor marker
shown to be overexpressed in several solid tumors including
prostate, ovarian, gastric, pancreatic and lung cancer. MM-310 uses
Merrimack's proprietary nanotherapeutics delivery platform to
provide controlled biodistribution and sustained exposure of a
proprietary docetaxel prodrug at the site of the tumor, potentially
allowing for improved antitumor activity while lowering exposure in
normal tissues and minimizing the hematologic toxicities common
with docetaxel or the vascular toxicity associated with a
traditional EphA2-targeted antibody drug conjugate (ADC) format.
Preclinical data to be presented at the conference include the
immunomodulatory effects of MM-310 in combination with a PD-1
inhibitor as well as tolerability and anti-tumor activity data on
MM-310 in combination with carboplatin.
Also highlighted at the conference will be preclinical data for
MM-141 (istiratumab), a monoclonal bispecific antibody that acts as
a tetravalent inhibitor of IGF1-R and HER3, and MM-161, a novel
first-in-class pan-FGFR antibody. Merrimack will also present data
on several other targeted therapies currently or previously in
development.
Poster Sessions
MM-310: A novel EphA2-targeted
nanotherapeutic delivering a proprietary docetaxel prodrug
- Session Title: Immunomodulatory Agents and
Therapeutics
Immunomodulatory effects of an
EphA2-targeted Docetaxel antibody-directed nanotherapeutic and
synergistic combination with PD-1 inhibitor (Abstract
#4711/27)
Tuesday, April 4, 2017, 1:00 PM
- 5:00 PM ET
Location: Section 30
- Session Title: Drug Delivery Technology and Antibody
Technology
Mechanisms of synergy of carboplatin and an
EphA2-targeted docetaxel antibody-directed nanotherapeutic
(Abstract #3096/7)
Tuesday, April 4, 2017, 8:00 AM
- 12:00 PM ET
Location: Section 4
Istiratumab (MM-141): A monoclonal antibody that
acts as a tetravalent inhibitor of PI3K/AKT/mTOR
- Session Title: Oncogenic Growth Factors and Signal
Transducers
Dual-targeting of IGF-1R and ErbB3 pathways
in Ewing's Sarcoma cellular models with istiratumab (MM-141), a
bispecific, tetravalent monoclonal antibody (Abstract
#521/7)
Sunday, April 2, 2017, 1:00 PM -
5:00 PM ET
Location: Section 22
MM-151: An oligoclonal therapeutic consisting of a
mixture of 3 fully human monoclonal antibodies designed to bind and
inhibit signaling of the epidermal growth factor receptor
(EGFR)
- Session Title: Novel Agents
Preclinical Update on
Targeting KRAS Wild-Type Colorectal Cancer with an EGFR-Targeted
Monoclonal Tri-body Mixture, MM-151 (Abstract #122/18)
Sunday, April 2, 2017, 1:00 PM -
5:00 PM ET
Location: Section 5
MM-161: A novel first-in-class pan-FGFR antibody
- Session Title: Antibodies, Bispecifics, and Antibody-Drug
Conjugates
MM-161, a first-in-class pan-FGFR antibody
(Abstract #22/3)
Sunday, April 2, 2017, 1:00 PM -
5:00 PM ET
Location: Section 2
Preclinical Research:
- Session Title: Bioinformatics and Analysis for Therapy and
Immune System
Estimation of immune cell content in bulk
tumor tissue using reference profiles from single-cell RNA-seq
data (Abstract #559/20)
Sunday, April 2, 2017, 1:00 PM -
5:00 PM ET
Location: Section 23
MM-398 (ONIVYDE® (irinotecan liposome injection) or
"Nal-IRI"): A novel encapsulation of irinotecan in a liposomal
formulation
- Session Title: Novel Drug Delivery Technology
Nanoliposomal irinotecan (nal-IRI, MM-398) has greater
anti-tumor activity than topotecan and irinotecan in mouse models
of small cell lung cancer (Abstract #5151/23)
Wednesday, April 5, 2017, 8:00
AM - 12:00 PM ET
Location: Section 5
- Session Title: Phase I-III Clinical Trials and Pediatric
Clinical Trials
Plasma pharmacokinetics of
liposomal irinotecan (nal-IRI) in pediatric oncology patients with
recurrent or refractory solid tumors: South Plains Oncology
Consortium Study 2012-001 (Abstract # CT146/27)
Tuesday, April 4, 2017, 1:00 PM
- 5:00 PM ET
Location: Section 33
About Merrimack
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking
cancer to ensure that patients and their families live fulfilling
lives. Our mission is to transform cancer care through the smart
design and development of targeted solutions based on the deep
understanding of cancer pathways and biological markers. All of our
product candidates, including three in clinical studies and several
others in preclinical development, fit into our three-pronged
strategy of 1) understanding the biological problems we are trying
to solve, 2) designing specific solutions and 3) developing those
solutions in biomarker-enriched homogenous patient populations.
Through systems biology, which brings together the fields of
biology, computing and engineering, Merrimack aims to decrease the
uncertainty in drug development and clinical validation. Such an
approach has the potential to make individualized treatment of
patients a reality. For more information, please visit Merrimack's
website at www.merrimack.com.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts, they are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements include any statements about Merrimack's
strategy, future operations, future financial position and future
expectations and plans and prospects for Merrimack, and any other
statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could,"
"should," "continue," "hope" and similar expressions. In this press
release, Merrimack's forward-looking statements include statements
about the potential effectiveness and safety profile of MM-310 and
Merrimack's ability to translate preclinical data into future
clinical success. Such forward-looking statements involve
substantial risks and uncertainties that could cause Merrimack's
development programs, future results, performance or achievements
to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the uncertainties inherent in the initiation of
future clinical trials, availability of data from ongoing clinical
trials, expectations for regulatory approvals, development progress
of Merrimack's companion diagnostics, availability of funding
sufficient for Merrimack's foreseeable and unforeseeable operating
expenses and capital expenditure requirements, and other matters
that could affect the availability or commercial potential of
Merrimack's products, product candidates or companion diagnostics.
Merrimack undertakes no obligation to update or revise any
forward-looking statements. Forward-looking statements should not
be relied upon as representing Merrimack's views as of any date
subsequent to the date hereof. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to Merrimack's business in general, see the "Risk
Factors" section of Merrimack's Annual Report on Form 10-K filed
with the Securities and Exchange Commission (SEC) on March 1, 2017 and other reports Merrimack files
with the SEC.
Contact:
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/merrimack-to-present-at-the-2017-american-association-for-cancer-research-annual-meeting-300429451.html
SOURCE Merrimack Pharmaceuticals, Inc.